Lupin seeks to acquire companies and brands globally

08 Jul 2013 Evaluate

Lupin, drug major is planning to acquire companies and brands globally, including companies in US, Japan and China, in order to increase its global footprint. It is taking a three-pronged approach in its acquisition strategy, which also includes the domestic market. With this initiative, the Mumbai-based firm aims to take over companies which can provide it new technology and market access.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

Lupin Share Price

2090.15 -23.95 (-1.13%)
15-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.25
Dr. Reddys Lab 1280.40
Cipla 1507.25
Zydus Lifesciences 921.25
Lupin 2090.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×